San Francisco-based medical technology company SoundHealth has secured $12.25 million in an oversubscribed Series A financing led by ShangBay Capital. The company plans to use the capital to expand the commercial reach of its artificial intelligence-enabled, non-invasive devices for breathing and sleep disorders. The financing also gives SoundHealth additional resources to develop personalized therapies designed as drug-free alternatives for large patient populations.
Funding Supports Commercial Expansion
SoundHealth is positioning the new investment as a growth round focused on scaling its existing product portfolio and widening adoption among consumers and healthcare professionals. ShangBay Capital, an investor specializing in medical devices, biotechnology, and digital health, will provide strategic support as the company advances its commercialization efforts. SoundHealth CEO Dr. Paramesh Gopi said the partnership could strengthen the company’s growth trajectory, while co-founder Dr. Bryant Lin highlighted the investor’s experience in helping medtech businesses scale.
Personalized Technology for Nasal Congestion
The company’s flagship product, the FDA De Novo-authorized SONU Band, is designed to provide non-pharmaceutical relief for moderate to severe nasal congestion associated with allergic and non-allergic rhinitis. Its companion application uses a smartphone facial scan to map a user’s anatomy, calculate personalized resonant frequencies, and guide the wearable’s acoustic vibration therapy. SoundHealth says the device has delivered more than 500,000 treatment sessions and is available for users aged 12 and older.
Building an Alternative to Medication
SONU applies sound waves and gentle vibrations to the nasal and sinus cavities, with the aim of reducing swelling, loosening mucus, and improving airflow without sprays or systemic medication. The company presents the product as an option for patients seeking to limit reliance on steroids or other pharmaceutical treatments, although individual outcomes can vary. More than 1,000 medical and dental professionals nationwide recommend SoundHealth’s technologies, according to the company.
Expanding Into Sleep Wellness
SoundHealth has also extended its personalization platform into sleep through Spatial Sleep, a wearable headband that uses tailored sounds and vibrations to support rest. The system creates an acoustic profile from a smartphone selfie and adjusts its output to the user’s craniofacial anatomy using machine-learning models and bone-conduction components. Company-reported clinical data indicate that the device can help users fall asleep faster, sleep longer, and improve perceived sleep quality.
A Data-Driven Product Platform
At the center of SoundHealth’s strategy is a proprietary craniofacial anatomical dataset developed to identify individual structural differences that may influence breathing and sleep. The company uses this information with artificial intelligence algorithms to generate personalized treatment settings rather than applying a uniform protocol to every user. SoundHealth believes the same technical foundation can support additional non-invasive products and broader applications across respiratory and sleep health.
Investor Rationale
ShangBay Capital founder William Dai said the investment reflects confidence in SoundHealth’s portfolio of FDA-authorized, AI-enabled therapeutics and its ability to address widespread health problems. He also pointed to the company’s dataset and proprietary algorithms as assets that could support future product development and commercial differentiation. The funding arrives as investors increasingly emphasize medical technologies with validated products, defined regulatory pathways, and visible routes to market.
The Series A gives SoundHealth fresh capital to accelerate sales, expand awareness, and continue developing personalized devices for breathing and sleep-related conditions. Its growth strategy combines regulated medical technology, consumer-friendly wearables, and artificial intelligence intended to tailor treatment to each user’s anatomy. Execution will now depend on the company’s ability to convert clinical validation and professional recommendations into sustained adoption across healthcare and consumer markets.